WO2002034736A1 - Process for preparation of bicyclic and polycyclic molecules - Google Patents
Process for preparation of bicyclic and polycyclic molecules Download PDFInfo
- Publication number
- WO2002034736A1 WO2002034736A1 PCT/AU2001/001379 AU0101379W WO0234736A1 WO 2002034736 A1 WO2002034736 A1 WO 2002034736A1 AU 0101379 W AU0101379 W AU 0101379W WO 0234736 A1 WO0234736 A1 WO 0234736A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- carbon atom
- iii
- subjecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CCC(CC(*)(C(C)(C)*(*C)[C@@]1*C)C2(*)*(C)=I)C1(*(C)C)C(*)(*)*(C)(C)C(C)(C)C2NCCC(C)*C Chemical compound CCC(CC(*)(C(C)(C)*(*C)[C@@]1*C)C2(*)*(C)=I)C1(*(C)C)C(*)(*)*(C)(C)C(C)(C)C2NCCC(C)*C 0.000 description 6
- NAYXHHVAKISCFY-UHFFFAOYSA-N C/[O]=C/c(cc1)ccc1NC1CCC=CCC1 Chemical compound C/[O]=C/c(cc1)ccc1NC1CCC=CCC1 NAYXHHVAKISCFY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Definitions
- NARC ring closures
- the invention provides a method of synthesis of a bicyclic or polycyclic compound of general formula I or general formula II
- E represents an electrophile
- each of R, R 1 , R 2 , R 3 , R 6 , R 7 , R 8 and R 9 independently represents hydrogen, alkyl, alkenyl, alkynyl, aryl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, hydroxy, alkoxy, alkenyloxy, aryloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, amino, alkylamino, dialkyla ino, alkenylamino, alkynylamino, arylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, acy
- W represents an electron withdrawing group
- X has the same definition as R
- Z represents 0, NR 15 , S or CR 16 W , where R 15 has the same definition as R and W has the same definition as W
- each of n and m represents an integer from 0 to 100; and the method comprises the steps of (a) activating a compound of general formula III;
- R, R ⁇ R 3 , W, X and Y are as defined above for the compounds of formulae I and II, and R 4 and R 5 each independently have the same definition as R; (b) subjecting a compound of general formula IV to nucleophilic addition by the activated form of compound III;
- R 6 -R 1:L and Z are as defined above for the compounds of formulae I and II, and R 10 and R 11 each independently have the same definition as R; (c) subjecting the product of step (b) to ring closing metathesis; and (d) subjecting the product of step (c) to stereoselective ring closure.
- alkyl used either alone or in a compound word such as "optionally substituted alkyl” or “optionally substituted cycloalkyl” denotes straight chain, branched or mono- or poly- cyclic alkyl. It will be clearly understood that the chain length of the alkyl group is not critical, and that in contrast to other types of organic syntheses, there appears to be no practicable upper limit. However, preferably the alkyl is C ⁇ _ 30 alkyl or cycloalkyl.
- straight chain and branched alkyl examples include methyl, ethyl, propyl, isopropyl, butyl, isbutyl, sec-butyl, tert-butyl, amyl, isoamyl, sec-amyl, 1, 2-dimethylpropyl, 1,1- dimethylpropyl , hexyl, 4-methylpentyl, 1-methylpentyl, 2- methylpentyl, 3-methylpentyl, 1, 1-dimethylbutyl , 2,2- dimethylbutyl , 3 , 3-dimethylbutyl, 1, 2-dimethylbutyl, 1,3- dimethylbutyl, 1, 2 , 2-trimethylpropyl, 1, 1, 2-trimethylpropyl, heptyl, 5-methylhexyl, 1-methylhexyl, 2 , 2-dimethylpentyl, 3 , 3-dimethylpentyl, 4, 4-dimetylpentyl, 1, 2-dimethylpent
- cyclic alkyl examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl and the like.
- the alkyl may optionally be substituted by any non-deleterious substituent .
- alkenyl used either alone or in compound words such as “alkenyloxy” denotes groups formed from straight chain, branched or cyclic alkenes including ethylenically mono-, di- or poly-unsaturated alkyl or cycloalkyl groups as defined above, preferably C2-20 alkenyl.
- alkenyl examples include vinyl, allyl, 1-methylvinyl, butenyl, iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl, 1-heptenyl, 3-heptenyl, 1-octenyl, cyclooctenyl, 1-ncnenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3- decenyl, 1, 3-butadienyl, l-4,pentadienyl, 1,3- cyclopentadienyl, 1, 3-hexadienyl, 1, 4-hexadienyl, 1,3- cyclohexadienyl, 1, 4-cyclohexaidenyl, 1, 3-cycloheptadienyl, 1, 3 , 5-cycloheptatrieny
- alkoxy used either alone or in compound words such as “optionally substituted alkoxy” denotes straight chain or branched alkoxy, preferably Cl-30 alkoxy. Examples of alkoxy include methoxy, ethoxy, n-propyloxy, isopropyloxy and the different butoxy iso ers.
- acyl used either alone or in compound words such as "optionally substituted acyl” or “optionally substituted acyloxy” denotes carbamoyl, aliphatic acyl group and acyl group containing an aromatic ring, which is referred to as aromatic acyl or a heterocyclic ring which is referred to as heterocyclic acyl, preferably Cl-30 acyl.
- acyl examples include carbamoyl ; straight chain or branched alkanoyl such as formyl, acetyl, propanoyl, butanoyl, 2- methylpropanoyl, pentanoyl, 2 , 2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl and icosanoyl; alkoxycarbonyl such as methoxycarbony1 , ethoxycarbony1 , t- butoxycarbonyl, t-pentyloxycarbonyl and heptyloxycarbonyl ; cycloalkylcarbony
- phenylacetyl phenylpropanoyl, phenylbutanoyl, phenylisobutyl, phenylpentanoyl and phenylhexanoyl
- naphthylalkanoyl e.g. naphthylacetyl, naphthylpropanoyl and naphthylbutanoyl
- aralkenoyl such as phenylalkenoyl (e.g.
- benzyloxycarbonyl ⁇ aryloxycarbonyl such as phenoxycarbonyl and naphthyloxycarbonyl ; aryloxyalkanoyl such as phenoxyacetyl and phenoxypropionyl; arylcarbamoyl such as phenylcarbamoyl; arylthiocarbamoyl such as phenylthiocarbamoyl; arylglyoxyloyl such as phenylglyoxyloyl and naphthylglyoxyloyl ; arylsulfonyl such as phenylsulfonyl and naphthylsulfonyl; heterocycliccarbonyl ; heterocyclicalkanoyl such as thienylacetyl, thienylpropanoyl, thienylbutanoyl, thienylpentan ⁇ yl, thienylhexan ⁇ yl
- aryl used either alone or in compound words such as "optionally substituted aryl", “optionally substituted aryloxy” or “optionally substituted heteroaryl” den ⁇ tes single, polynuclear, conjugated and fused residues of aromatic hydrocarbons or aromatic heterocyclic ring systems .
- aryl examples include phenyl, biphenyl, terphenyl, quaterphenyl, phenoxyphenyl, naphtyl, tetrahydronaphthyl, anthracenyl, dihydroanthracenyl, benzanthracenyl, dibenzanthracenyl, phenanthrenyl, fluorenyl, pyrenyl, indenyl, azulenyl, chrysenyl, pyridyl, 4-phenylpyridyl, 3- phenylpyridyl, thienyl, furyl, pyrryl, pyrrolyl, furanyl, imadazolyl, pyrrolydinyl , pyridinyl, piperidinyl, indolyl, pyridazinyl, pyrazolyl, pyrazinyl, thiazolyl, pyrimidinyl, quinoliny
- heterocyclyl used either alone or in compound words such as “optionally substituted saturated or unsaturated heterocyclyl” denotes monocyclic or polycyclic heterocyclyl groups containing at least one heteroatom atom selected from nitrogen, sulphur and oxygen.
- Suitable heterocyclyl groups include N-containing heterocyclic groups, such as, unsaturated 3 to 6 membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl or tetrazolyl; saturated 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms, such as, pyrrolidinyl, imidazolidinyl, piperidino or piperazinyl; unsaturated condensed heterocyclic groups containing 1 to 5 nitrogen atoms, such as indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl or tetrazolopyridazin
- optionally substituted means that a group may or may not be further substituted with one or more groups selected from alkyl, alkenyl, alkynyl, aryl, halo, haloalkyl, haloalkenyl, haloalkynyl, haloaryl, hydroxy, alkoxy, alkenyloxy, aryloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, nitro, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, amino, alkylamino, dialkylamino, alkenylamino, alkynylamino, arylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, acylamino, diacylamino,
- non-deleterious subsitituent refers to any of the substituents outlined above which does not interfere with the formation of the target compound or has not interfered with the formation of the subject compound.
- Preferred substituents are selected from the group consisting of halo, hydroxy, amino, nitro, cyano, mono- or di alkylamino, mono- or diarylamino, alkoxy, aryloxy, thioalkoxy, thiaryloxy, or is one or more alkyl, alkenyl, alkynyl, aryl, or alkylheteryl groups, each of which may be saturated or unsaturated.
- Halo or halogen means chloro, bro o, fluoro, or iodo.
- the electrophile may be of any suitable known type, such as, for example, those electrophiles disclosed in J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4 th Edition, John Wiley & Sons, New York, 1992 p 205.
- the electrophile may be organic or organometallic.
- the electrophile is selected from the group consisting of H, hydroxy, alkoxy, acyl, acyloxy, alkylsulphonyloxy, arylsulphenyloxy, hetercyclyloxy, carbcalkoxy, carboaryloxy, alkylthio, benzylthio, acylthio, cyano, halo, aryloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, acids or esters of phosphorous or sulphur, and metal salts, such as AuHal, HgHal, PdHal, SHal, and SeHal.
- the electron-withdrawing group or groups (W and W ) may also be of any suitable known type, such as, for example, one of the electron-withdrawing groups disclosed in J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4 th Edition, John Wiley & Sons, New York, 1992 ppl8-19.
- the electron-withdrawing group could therefore be selected from the group consisting of alkenyl, alkynyl, aryl, halo, haloalkenyl, haloalkynyl, haloaryl, alkoxy, alkenyloxy, aryloxy, benzyloxy, haloalkoxy, haloalkenyloxy, haloaryloxy, nitro, nitroalkenyl, nitroalkynyl, nitroaryl, nitroheterocyclyl, alkylamino, dialkylamino, alkenylamino, alkynylamin ⁇ , arylamino, diarylamino, benzylamino, dibenzylamino, acyl, alkenylacyl, alkynylacyl, arylacyl, acylamino, diacylamino, acyloxy, alkylsulfonyl ⁇ xy, arylsulfenyloxy, hetero
- the electron withdrawing group contains a chiral auxiliary.
- a chiral auxiliary is a group which is attached temporarily to a molecule in order to influence the stereoselectivity of one or more synthetic transformations.
- a full description of the way in which chiral auxiliaries influence stereoselectivity of reactions can be found in G. Lin, Y. Li . A.S.C. Chan, Principals and Applications of Asymmetric Synthesis, Wiley Interscience, New York, 2001, pp49-53, D. A. Evans, V. J. Nelson, E. Vogel, T. R. Taber, J. Am. Chem, . Soc . , 1981, 103, 3099-3111, W. Oppolzer, J. Blagg, I. Rodriguez, e.
- Suitable chiral auxiliaries may be selected from one of the chiral auxiliaries disclosed in the Lin et al text referred to above. Some specific examples used by the applicant are Oppolzer' s sultam (Oppolzer et al . , 1990),
- the auxiliary is attached to the compound via the nitrogen atom (with removal of the hydrogen atom) .
- a chiral auxiliary may also be advantageously used in other lecations of the compound during synthesis .
- each of n and m represents an integer from 0 to 50, more preferably 0 to 25.
- the compound may be a carbocycle, oxacycle, azacycle or thiacycle, and is preferably a compound selected from the group consisting of monosaccharides, oligosaccharides, tropane alkaloids, cyclic ⁇ - and/or ⁇ -amino acids, squalestatins, zaragozic acids, fumagillins, and analogues thereof.
- steps (a) and (b) the methods employed for activating the compound of general formula III and conducting the nucleophilic addition may be varied as necessary according to the nature of the electron withdrawing group W. Suitable methods are well known in the art, for example by reference to March, J. in Advanced Organic
- One option for conducting steps (a) and (b) requires X to be hydrogen, and the method involves treating the compound of formula III with a base in order to generate the corresponding enolate.
- G in the compound of formula I or II will be the electron withdrawing group W.
- step (c) the term “ring closing metathesis” is to be understood to mean the coupling of two tethered alkenes to form a ring comprising a new alkene, with concomitant loss of an alkene (Grubbs and Chang 1998; Schuster and Bleichert 1997; Schwab et al, 1996) .
- Enantiomeric selectivity in step (b) may be achieved in two ways .
- Either one or both of the starting compounds of formulae III and IV is chiral, or an enantiomerically-enriched additive system is used to promote stereoselective coupling of the compounds of formulae III and IV.
- the additive may be a catalyst or a promoter, and may be present in an amount ranging from sub-stoichiometric to stoichiometric or greater.
- the additive may be a catalyst.
- the additive includes but is not limited to Sn (II) salts in combination with chiral, non-racemic diamine ligands (Kobayashi at al, 1989, 1994), chiral, non-racemic Binol metal complexes (Yamada et al, 1998; Mika i et al, 1993) and chiral, non-racemic metal complexes of semicorrins (Evans, 1999) .
- the final step of the procedure involves the formation of the second ring by creating a bridge across the cycloalkene, with the consequent saturation of the alkenyl double bond.
- the cyclisation reactions are diastereoselective, ie they rely on the structures of the starting materials to induce chirality in the newly-formed ring.
- a typical example of this reaction is intramolecular oxymercuration.
- Suitable reagents for conducting this final step include electrophiles, such as metal salts, eg HgCl 2 , Hg(OCOR) 2 , PdCl 2 ; halogens, eg Br 2 , Cl 2 , I 2 ; peracids, eg RC0 3 H, ArC0 3 ; and electrophilic selenating reagents eg PhSeBr.
- electrophiles such as metal salts, eg HgCl 2 , Hg(OCOR) 2 , PdCl 2 ; halogens, eg Br 2 , Cl 2 , I 2 ; peracids, eg RC0 3 H, ArC0 3 ; and electrophilic selenating reagents eg PhSeBr.
- electrophiles such as metal salts, eg HgCl 2 , Hg(OCOR) 2 , PdCl 2 ; halogens, e
- E, R, R 1 - R 11 , G, W, X, Y and Z are as defined above .
- E, R, R 1 - R 11 , G, X, W and Y are as defined above for the compounds of formulae I, II, III and IV, and Z' is N or CW", where W" has the same definition as W.
- the present invention accordingly provides a method of forming a compound with two rings, with carbon atoms C and C b , or carbon atoms C a and C c , being common to the two rings, the method comprising:
- step (e) subjecting the product of step (d) to ring closing methathesis to thereby connect carbon atoms C b and C c via a double bond; and (f) subjecting the product of step (e) to stereoselective ring closure to form a bridge between C and one or both of C b and C c with the loss of the alkenyl bond between C b and C c to yield said compound containing two rings .
- the fragments of the first compound between carbon atcms C c and C d may be of any constitution that does not interfere with the subsequent reactions being conducted to form the target compound. Accordingly, the fragment may contain a substituted or unsubstituted, branched, unbranched or cyclic hydrocarbon group, optionally interspersed with one or more 0, N and S atoms.
- the substituents may be any one of the non-deleterious substituents as defined above, or may be the protected form of one of the broader range of possible substitutents that could interfere in the reactions for forming the two rings if not protected.
- the fragments of the second compound between carbon atoms C a and C b may likewise be of any constitution that does not interfere with the subsequent reactions being conducted to form the target compound. Accordingly, the fragment may contain a substituted or unsubstituted, branched, unbranched or cyclic hydrocarbon group, optionally interspersed with one or more 0, N and S atoms.
- the substituents may be any one of the non-deleterious substituents as defined above, or may be the protected form of one of the broader range of possible substitutents that could interfere in the reactions for forming the two rings if not protected.
- step (d) the end fragments joined to C b and C c via the respective double bonds prior to the ring closing metathesis are disconnected. Accordingly these fragments of the first and second compounds may be of any constitution provided that they do not interfere with steps (c) , (d) and (e) .
- the electron withdrawing group attached to C d in the first compound can be any of the well-known electron withdrawing groups known in the art, and therefore has the same definition as W in formulae I and II outlined above.
- Steps (c) and (d) may be conducted by activating the first compound using a base to form an enolate and reacting this with the second compound.
- the electron withdrawing group includes a chiral auxiliary radical.
- the electron-withdrawing group is a halogen
- C d is activated by reacting the first compound with magnesium to form the corresponding organomagnesium halide, or by reacting the first compound with another suitable reagent (such as lithium metal) to form the correspending organometallic reagent.
- the substituent attached tc carbcn atom C of the second compound is preferably selected from the group consisting of 0, NR 17 , CR 18 W X and S, when the substituent is connected via a double bond, and N or CW y when the substituent is connected via a triple bond, wherein R 17 and R 18 each have the same definition as R in formula I, and W x and W y each have the same definition as W in formula I .
- target compounds Selected examples of target compounds and their starting materials are set out in Table 1 below.
- the target compounds may be derivatives of the compounds of formulae I or II.
- the substituents R, W, X, G and Z as well as the descriptors and n have the same definitions as those set out above for the compounds of formulae I and II . Only skeleton structures for the target molecules are shown; it will be clearly understood that each may contain one or more of the substituents R 1 to R 11 and E set out above for formulae I and II. It is also to be noted that some of the compounds set out below may include further hydrocarbon rings, as denoted by the hydrocarbon groups with the descriptor p. "p" has the same definition as m and n in Formulae I and II.
- the compounds described herein are useful either as lead candidates for pharmaceutical or agrochemical development, or as intermediates in synthesis of other compounds .
- Methods of screening of candidate compounds for useful biological or pharmacological activity are very widely known in the art. See for example Tait (1992) .
- the assays to be used and the threshold activity regarded as useful will depend on the nature of the compound and the specific assay and activity used.
- the invention provides a library of compounds suitable to be tested for a desired biological or pharmacological activity, comprising a plurality of compounds prepared by the method of the invention.
- the compound is in enantiomerically pure form. More preferably the compound is produced by the method of the invention.
- a solution of diethyl boron triflate was generated by dropwise addition of freshly distilled triflic acid (440 ⁇ l, 5.0mmol) to triethyl borane (IM in hexane, 5ml, 5.0mmol) .
- the solution was stirred at RT for 20 minutes until mostly homogeneous. If the solution is not homogeneous, it may be warmed at approx. 40° for 20 min.
- the triflate solution was cooled to -5° and a solution of the acyl sultam (1) (743mg, 2.5mmol) in dichloromethane (5ml) , followed by a solution of ⁇ -di isopropyl ethylamine (IM in dichloromethane, 5ml, 5.0mmol) were added. After stirring at - 5°for 20 minutes the solution was co ⁇ led to -78° and a solution of the aldehyde (2) (610mg, 3.8mmol) in dichlor ⁇ ethane (1ml) was added. After stirring for 2 hours the reaction was quenched by addition of 0.5M pH 7 phosphate buffer (10ml) and left to warm to RT.
- IM ⁇ -di isopropyl ethylamine
- IR (nujol/ CH2CI2 film): 3495, 2923, 2854, 1685, 1461, 1377, 1335, 1267, 1237, 1213, 1166, 1134, 1066, 992, 917, 769, 740, 701cm- 1 .
- the reaction was quenched by addition of 0.5M pH 7 phosphate buffer (12ml) , taken up in ether (30ml) , the aqueous layer separated and the organic layer washed with sat. NH4CI (2x 50ml) . After drying (MgS04) and removal of solvent in vacuo (at ambient temperature) the aldol adduct was purified by column chromatography eluting hexane/ ethyl acetate (5:1). The aldol adduct (5) was obtained as an oil 853mg, 70%.
- IR (nujol/ CH2CI2 film): 3528, 3075, 2926, 1682, 1458, 1415, 1377, 1336, 1266, 1236, 1213, 1166, 1135, 1065, 1040, 992, 912, 739 cm "1 .
- the aldol adduct (4) (98mg, 0.2mmol) was dissolved in degassed dichloromethane (15ml) under argon. A solution of Grubbs' catalyst (17mg, 0.02mmol) in dichloromethane (1ml) was added and the reaction stirred overnight. Evaporation of the solvent, followed by chromatography eluting hexane/ ethyl acetate (4:1), gave the cycloheptene (6) as colourless crystals 59mg, 79%.
- the aldol adduct (5) (484mg, 1.22mmol) was dissolved in degassed dichlor ⁇ methane (390ml) under argon. A solution of Grubbs ' catalyst (85mg, O.lmmol) in dichloromethane (10ml) was added and the reaction stirred at 50° for 60 hours. Evaporation of the solvent, followed by chromatography eluting hexane/ ethyl acetate (4:1), gave the cyclooctene (7) as colourless crystals 193mg, 43%. Rf (0.55) in hexane/ ethyl acetate (2:1), mp 153-155°. [a D ]-78° (c 0.8, CH2CI2) .
- IR (nujol/ CH2CI2 film): 3528, 3055, 2927, 1670, 1456, 1414, 1334, 1285, 1236, 1214, 1165, 1133, 1063, 896, 744 cm -1 .
- the cycloalkene (6) (109mg, 0.31mmol) was dissolved in dichloromethane (25ml) and Hg(OAc)2 (99mg, 0.31mmol) was added. The mixture was stirred at RT overnight after which a solution of sat. NaCl (10ml) was added and the reaction stirred for at least 1 hour more.
- IR (nujol) 3500, 2924, 2854, 1695, 1461, 1378, 1318, 1203, 1127cm- 1 .
- the cycloalkene (7) (160mg, 0.43mmol) was dissolved in dichloromethane (40ml) and Hg(OAc)2 (153mg, 0.48mmol) was added. The mixture was stirred at RT overnight after which a solution of sat. NaCl (10ml) was added and the reaction stirred for at least 1 hour more.
- IR (nujol/ CH2CI2 film): 3438, 2926, 2854, 1686, 1458, 1377, 1327, 1265, 1235, 1211, 1164, 1132, 1060, 1023, 982, 845, 772, 736 cm -1 .
- IR (nujol/ CH2CI2 film) : 3441, 2925, 2634, 1686, 1459, 1377, 1330, 1264, 1213, 1165, 1132, 1053, 986, 904, 743cm- 1 .
- IR CH2CI2 film: 3054, 2962, 1698, 1422, 1329, 1266, 1209, 1132, 1064, 989cm" 1 .
- IR (nujol/ CH2CI2 film) : 3228, 2925, 2854, 1735, 1466, 1377, 1209, 1169, 1106, 1020, 986, 866, 748cm- 1 .
- the p-anisidine i ine of 4-pentenal was prepared by addition of p-anisidine (458 mg, 3.72 mmol) to an ice cold solution of 4-pentenal (317 mg, 3.72 mmol) in diethylther (3.5 ml) . After stirring in the cold for 15 minutes, 4 pellets of KOH were added and the mixture was stirred for an additional 15 minutes. The crude imine solution was obtained by filtering the solution from the solid KOH. 4-Bromo-l-butene (755 ⁇ L, 7.4 mmol) was added to a solution of magnesium(200 mg, 8.2 mmol) in dry THF (13ml) under nitrogen atmosphere with stirring at room temperature.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002427021A CA2427021A1 (en) | 2000-10-27 | 2001-10-26 | Process for preparation of bicyclic and polycyclic molecules |
| AU1364302A AU1364302A (en) | 2000-10-27 | 2001-10-26 | Process for preparation of bicyclic and polycyclic molecules |
| EP01981942A EP1334092B1 (en) | 2000-10-27 | 2001-10-26 | Process for preparation of bicyclic and polycyclic molecules |
| JP2002537727A JP2004511577A (ja) | 2000-10-27 | 2001-10-26 | 二環式及び多環式分子の調製方法 |
| DE60128382T DE60128382D1 (de) | 2000-10-27 | 2001-10-26 | Verfahren zur herstellung von bicyclischen und polycyclischen molekülen |
| US10/423,563 US7012142B2 (en) | 2000-10-27 | 2003-04-25 | Process for preparation of bicyclic and polycyclic molecules |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR1057A AUPR105700A0 (en) | 2000-10-27 | 2000-10-27 | Process for preparation of bicyclic and polycyclic molecules |
| AUPR1057 | 2000-10-27 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/423,563 Continuation US7012142B2 (en) | 2000-10-27 | 2003-04-25 | Process for preparation of bicyclic and polycyclic molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2002034736A1 true WO2002034736A1 (en) | 2002-05-02 |
Family
ID=3825101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/AU2001/001379 Ceased WO2002034736A1 (en) | 2000-10-27 | 2001-10-26 | Process for preparation of bicyclic and polycyclic molecules |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7012142B2 (https=) |
| EP (1) | EP1334092B1 (https=) |
| JP (1) | JP2004511577A (https=) |
| AU (2) | AUPR105700A0 (https=) |
| CA (1) | CA2427021A1 (https=) |
| DE (1) | DE60128382D1 (https=) |
| WO (1) | WO2002034736A1 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| US11767337B2 (en) | 2020-02-18 | 2023-09-26 | Gilead Sciences, Inc. | Antiviral compounds |
| US12030903B2 (en) | 2020-02-18 | 2024-07-09 | Gilead Sciences, Inc. | Antiviral compounds |
| US12054507B2 (en) | 2020-02-18 | 2024-08-06 | Gilead Sciences, Inc. | Antiviral compounds |
| US12116380B2 (en) | 2021-08-18 | 2024-10-15 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101620137B1 (ko) * | 2013-06-14 | 2016-05-12 | 주식회사 엘지화학 | 플러렌 유도체의 제조 방법 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997040859A1 (en) * | 1996-04-26 | 1997-11-06 | President And Fellows Of Harvard College | Bridge-substituted tropanes and uses |
| WO1999002526A1 (en) * | 1997-07-11 | 1999-01-21 | Organix, Inc. | Tropane analogs and methods for inhibition of monoamine transport |
-
2000
- 2000-10-27 AU AUPR1057A patent/AUPR105700A0/en not_active Abandoned
-
2001
- 2001-10-26 AU AU1364302A patent/AU1364302A/xx not_active Withdrawn
- 2001-10-26 WO PCT/AU2001/001379 patent/WO2002034736A1/en not_active Ceased
- 2001-10-26 JP JP2002537727A patent/JP2004511577A/ja active Pending
- 2001-10-26 DE DE60128382T patent/DE60128382D1/de not_active Expired - Lifetime
- 2001-10-26 EP EP01981942A patent/EP1334092B1/en not_active Expired - Lifetime
- 2001-10-26 CA CA002427021A patent/CA2427021A1/en not_active Abandoned
-
2003
- 2003-04-25 US US10/423,563 patent/US7012142B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997040859A1 (en) * | 1996-04-26 | 1997-11-06 | President And Fellows Of Harvard College | Bridge-substituted tropanes and uses |
| WO1999002526A1 (en) * | 1997-07-11 | 1999-01-21 | Organix, Inc. | Tropane analogs and methods for inhibition of monoamine transport |
Non-Patent Citations (7)
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11767337B2 (en) | 2020-02-18 | 2023-09-26 | Gilead Sciences, Inc. | Antiviral compounds |
| US12030903B2 (en) | 2020-02-18 | 2024-07-09 | Gilead Sciences, Inc. | Antiviral compounds |
| US12054507B2 (en) | 2020-02-18 | 2024-08-06 | Gilead Sciences, Inc. | Antiviral compounds |
| US12264173B2 (en) | 2020-02-18 | 2025-04-01 | Gilead Sciences, Inc. | Antiviral compounds |
| US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| US12116380B2 (en) | 2021-08-18 | 2024-10-15 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004511577A (ja) | 2004-04-15 |
| AUPR105700A0 (en) | 2000-11-23 |
| DE60128382D1 (de) | 2007-06-21 |
| US20040010140A1 (en) | 2004-01-15 |
| AU1364302A (en) | 2002-05-06 |
| EP1334092A4 (en) | 2004-08-11 |
| US7012142B2 (en) | 2006-03-14 |
| EP1334092A1 (en) | 2003-08-13 |
| CA2427021A1 (en) | 2002-05-02 |
| EP1334092B1 (en) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2285103T3 (es) | N-biarilamidas aza-biciclicas con afinidad por el receptor nicotinico de acetilcolina alfa7. | |
| AU2021209257B2 (en) | Bicyclic BET bromodomain inhibitors and uses thereof | |
| ES2319797T3 (es) | Derivados de pirazolopiridina. | |
| DE69111138T2 (de) | Heterocyclische Verbindungen mit antiemetischer und Migräne unterdrückender Wirkung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen. | |
| TWI886406B (zh) | 介白素-1受體相關激酶之雙官能降解劑及其治療用途 | |
| WO1993013083A1 (en) | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity | |
| CA2910873A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| KR20070002006A (ko) | Hiv 인테그라제 억제제 | |
| BR112020008157A2 (pt) | compostos espirocíclicos como moduladores do receptor farnesoide x | |
| EP1334092B1 (en) | Process for preparation of bicyclic and polycyclic molecules | |
| AU2014228574A1 (en) | SHIP1 modulators and methods related thereto | |
| CN102712641B (zh) | Mk2抑制剂 | |
| EP1090008A1 (en) | Syntheses of a variety of lamellarin compounds and analogues | |
| AU2019251148A1 (en) | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | |
| AU2002213643B2 (en) | Process for preparation of bicyclic and polycyclic molecules | |
| AU2002213643A1 (en) | Process for preparation of bicyclic and polycyclic molecules | |
| EP0981517B1 (en) | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides | |
| CN101641356B (zh) | 氮杂金刚烷的乙酰胺和甲酰胺衍生物及其使用方法 | |
| AU755919C (en) | Syntheses of a variety of lamellarin compounds and analogues | |
| WO2004011473A1 (en) | Organogermanium compounds and methods for their use | |
| US6696611B2 (en) | Chemical methods | |
| CN115403581B (zh) | 作为irak4抑制剂的杂环化合物 | |
| AU7017098A (en) | Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents | |
| WO2004065334A1 (en) | Method of removing organotin residue | |
| US20030166979A1 (en) | Chemical methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 10423563 Country of ref document: US Ref document number: 2427021 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002537727 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002213643 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001981942 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001981942 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2001981942 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2002213643 Country of ref document: AU |